The industry responsible for bringing testing to the public isn’t relying on it to go back to work. BioCentury’s survey finds that as biopharma companies begin to reopen their doors to employees, they aren’t going...

The WHO’s decision-making body adopted a sweeping resolution this week aimed at unifying the global response to the COVID-19 pandemic. The U.S. was not one of the more than 130 countries that co-sponsored the World...

Four months after China signed a “Phase One” trade deal with the U.S., patent law amendments may not be among the priorities of the National People’s Congress, leaving it unclear when expected pharmaceutical patent protections...

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...

As the U.S. seeks to secure its supply chain following global disruptions from the COVID-19 pandemic, two Republican lawmakers are backing legislation that would enact a tax incentive to encourage manufacturers to keep production domestic....

While they race to create COVID-19 vaccines, governments, drug companies and the public health community must avoid a deadly mistake that has limited the effectiveness of other vaccines. From the moment a new medical product...

Combined virus and antibody testing is our best opportunity to identify those who can immediately but carefully return to work, and in doing so restart the economy while minimizing the epidemic’s resurgence. We argue that...

In the latest edition of the BioCentury This Week PODCAST , BioCentury Editor in Chief Simone Fishburn talks to Washington Editor Steve Usdin about the appointments of Michelle McMurry-Heath as CEO of BIO, Moncef Slaoui as...

As calls to pool countermeasures against COVID-19 grew Monday and Beijing committed $2 billion to the WHO, Washington continues to show little interest in cooperating with other governments via the world body to stem the...

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...

Moncef Slaoui, the former GSK executive named chief scientist of the COVID-19 vaccine acceleration program, said he has “seen early data from a clinical trial” that gave him confidence “that we will be able to...

BIO has picked a new president and CEO, Michelle McMurry-Heath, who breaks the Washington trade association mold. She will take over on June 1 from Jim Greenwood, who has held the position since 2004; she...

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...

COVID-19 is testing FDA’s leadership. The agency’s performance will affect both the health of COVID-19 patients as well as public trust in the agency. One of many challenges facing FDA is whether to keep in...

As the world eyes a return to post-COVID crisis “normalcy,” a robust global recovery will depend on effective treatments and ultimately a vaccine. Yes, more than 400 research and clinical programs are already under way,...